We’ll see. It sounds grandeur. Realistic. Not so sure. Speciality Rx only viable option. Not addressed. Super simple and not rocket science. Redundant. Exclusivity to Voquezna. Not PCABs. A Korean company is getting ready to launch their PCAB in the U.S Q1 2026. So while the company has autonomy now. This will change. That’s an absolute.